中 | EN
Home
About
Products
R&D
Manufacturing
Partnering
News
IR
Sustainability
Join Us

News

QUVIVIQ® - The World’s New Generation Anti-Insomnia Drug – Approved for Launch，Significantly Improves Sleep and Daytime Functioning

On June 20, 2025, Simcere Pharmaceutical (2096.HK) announced that QUVIVIQ® (generic name: Daridorexant Hydrochloride Tablets), an anti-insomni...

2025-06-23
Simcere Zaiming Announces First Patient Dosed in the US in a Phase 1 Trial of Trispecific Antibody SIM0500 in Patients with Relapsed/Refractory Multiple Myeloma

Shanghai, China, June 18, 2025 — Simcere Zaiming, an innovative oncology-focused subsidiary of Simcere Pharmaceutical Group (2096.HK) today announc...

2025-06-19
Simcere Zaiming and NextCure Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6

- NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rights- ...

2025-06-16
2025 ASCO | Simcere Zaiming Showcases the Latest Clinical Data in 18 Studies for 5 Innovative Products

The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago from May 30 to June 03 2025 is one of the most important globa...

2025-06-09
read more

6,500+

Staff

40+

Current Brands of Products

50+

Innovative Product Candidates

1,900+

Covering Class III Hospitals

17,000+

Covering Other Hospitals & Medical Institutions

Partnering

Therapeutic Areas

Telephone: 025-85566666

Address: 699-18 Xuanwu Avenue Nanjing China

Zipcode：210042

Fax：025-85471729

Su ICP Bei No. 10205883 Su Gong Wang An Bei No. 32010202010345
Su ICP Bei No. 08104641-3 | (Su)–Non-business–2018-0092 (Internet Drug Information Service Qualification Certificate)
© Copyright 2016 Jiangsu Simcere Pharmaceutical Co., Ltd. 版权所有 All Rights Reserved.